COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer

Grants

Funding Acknowledgements

The work of UK groups is supported by grants from Cancer Research UK and the European Union. In Spain, work is supported by grants from the Instituto de Salud Carlos III, grants FIS 05/1006, 08/1359, 08/1635 and European Commission FP6 Food-CT-2006-036224 (VM). In Canada, work is supported by grants from Genome Canada (the ARCTIC Project), the National Cancer Institute of Canada (the CaRE Project) and the Ontario Institute for Cancer Research. In Finland, work is supported by grants from Academy of Finland (Finnish Centre of Excellence Program 20062011), the Sigrid Juselius Foundation, the Finnish Cancer Societies and by the European Union. The work of DFKS is supported by the German Genome Network (NGFNplus). In the Czech Republic, work is supported by GACR 310/07/1430. In Sweden, work is supported by grants from the Swedish Cancer Foundation and the Swedish Research Council. In Barcelona and Santiago (Epicolon), work is supported by grants from Fondo de Investigacion Sanitaria (FIS 04/1126, 05/2031, 05/0071, 08/0025, 08/1276), Xunta de Galicia (PGIDIT07PXIB9101209PR), Fundacion de Investigacion Medica Mutua Madrilena (CRP and SCB), Ministerio de Educacion y Ciencia (SAF 07-64873), Asociacion Espanola contra el Cancer, Fundacion Olga Torres (SCB) and Accion Transversal contra el Cancer (Instituto de Salud Carlos III). CIBERER and CIBEREHD are funded by the Instituto de Salud Carlos III. SCB is supported by a contract from the Fondo de Investigacion Sanitaria (CP 03-0070, Ministerio de Sanidad. Provision of genotyping is gratefully provided by Santiago de Compostela node of the Spanish National Genotyping Center (CeGen). In The Netherlands, work of RH is supported by the Dutch Cancer Society and the European Community, and the work of JTW, TvW, HM and PD is supported by the Dutch Cancer Society (UL2005-3247) and Fonds NutsOhra. In Hong Kong, work is supported by grants from the Michael and Betty Kadoorie Cancer Genetics Research Programme II and by the Bobby Moore Fund of Cancer Research UK. Work in Australia is conducted under the auspices of the Hilton Ludwig Cancer Metastasis Initiative and supported by a grant from the NHMRC (Project Grant 489418). In Japan, this work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government. The ESTHER and VERDI studies are supported by grants from the Baden Wurttemberg Ministry of Research, Science and Arts and the German Cancer Aid (Deutsche Krebshilfe, Grant M24/95/BR I). The Kiel cohort (POPGEN) is funded through the German Ministry of Education and Reserach through the POPGEN Biobank grant and the Colon Cancer Network of the German National Genome Research Network. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as by the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant no. 03ZIK012) and by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of Siemens AG. MME, AV and LC-C have received funding from Cancer Research UK and Universidad del Tolima.In Italy, collection of samples and clinical data of individuals recruited at Fondazione IRCCS, Istituto Nazionale Tumori was possble because of efforts by Lucio Bertario, Paola Sala, Silvia Veneroni, Manuela Gariboldi, Fernando Ravagnani, Tiziana Camerini, Maria Gaetana Di Mauro, Maria Grazia Daidone and Marco A Pierotti. This study is supported by grants from Associazione/Fondazione Italiana per la Ricerca sul Cancro (AIRC/FIRC) and Lega Italiana per la Lotta ai Tumori.